WallStreetZenWallStreetZen

NASDAQ: CARM
Carisma Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Carisma Therapeutics revenue was $19.63M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2024) ending on Dec 31, 2024 was $3.7M, up 7.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CARM annual revenue was $19.6M, with 31.6% growth year-over-year.

CARM past revenue growth

How has CARM's revenue growth performed historically?

Company
31.59%
Industry
497.69%
Market
20.68%
CARM's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CARM's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CARM's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CARM revenue history

Current Revenue
$19.6M
Current Earnings
-$60.5M
Current Profit Margin
-308.1%

Be the first to know when CARM announces revenue.

CARM Revenue History By Year

CARM Yearly RevenueCARM RevenueCARM ChangeCARM Revenue Growth
2024-12-31$19.63M$4.71M+31.59%
2023-12-31$14.92M$5.09M+51.71%
2022-12-31$9.83M-$16.71M-62.95%
2021-12-31$26.54M$15.31M+136.24%
2020-12-31$11.24MN/AN/A
2019-12-31$0.00N/AN/A
2018-12-31$0.00-$425.00k-100.00%
2017-12-31$425.00k-$29.56M-98.58%
2016-12-31$29.98M$28.99M+2,928.38%
2015-12-31$990.00k-$1.25M-55.86%
2014-12-31$2.24M$909.00k+68.14%
2013-12-31$1.33MN/AN/A
2012-12-31$0.00N/AN/A
2011-12-31$0.00N/AN/A

1 of 1

Carisma Therapeutics Revenue FAQ

What was CARM's revenue last quarter?

On Invalid Date, Carisma Therapeutics (NASDAQ: CARM) reported Q4 2024 revenue of $3.65 million up 14.83% year over year. In the same quarter last year, Carisma Therapeutics's revenue was $4.29 million.

What was Carisma Therapeutics's revenue in 2024?

Carisma Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $19.63 million, a 31.59% increase year over year.

How much does Carisma Therapeutics make in a day?

Based on Carisma Therapeutics annual revenue for the past five years, CARM makes an average of $45,021.92 per day.

What was Carisma Therapeutics's annual revenue growth in the past year?

As of Q2 2025, Carisma Therapeutics's revenue has grown 31.59% year over year. This is 466.1 percentage points lower than the US Biotechnology industry revenue growth rate of 497.69%. Carisma Therapeutics's revenue in the past year totaled $19.63 million.

How much does Carisma Therapeutics make in a year?

Carisma Therapeutics's revenue by year for the past five years is:
  • Carisma Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $19.63 million, a 31.59% increase year over year.
  • Carisma Therapeutics's annual revenue for Dec 31, 2023 was $14.92 million, a 51.71% increase from 2022.
  • Carisma Therapeutics's annual revenue for 2022 was $9.83 million, a 62.95% decrease from 2021.
  • Carisma Therapeutics's annual revenue for 2021 was $26.54 million, a 136.24% increase from 2020.
  • Carisma Therapeutics's annual revenue for 2020 was $11.24 million, a Infinity% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.